Advances in the treatment of coronary artery disease remained steady in 2025, as in recent years, but the past 12 months also ...

A recent opinion paper concluded that timely revascularization and dual antiplatelet therapy (DAPT) are crucial in the ...

Findings of reduced risks for mortality and major CVD suggest consideration of statins in all adults with type 2 diabetes, even in those with low short-term predicted CVD risk.

AI and digital health devices should not be viewed as replacements for health care professionals, but as tools that can be ...

Preliminary but promising.Those three words emerged as a recurring theme in conversations about several abstracts presented at this year’s ASH Annual Meeting and Exposition that examined the effects ...

Drs Harrington and Gibson’s annual review of cardiovascular medicine: ACS guidelines, antiplatelet management, GLP-1s, and ...

According to Trump, he takes the popular medication regularly for his cardiovascular health -- but this practice is not ...

Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.

In a large randomized trial involving patients with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide in reducing ...

Heart attack care is entering a phase where machines do not just assist doctors, they anticipate the next move. A new ...

The approval marks the first new stroke treatment authorized in nearly 27 years, offering an additional option for managing acute ischemic stroke in Canada. MISSISSAUGA, ON, Dec. 17, 2025 /CNW/ - ...

Bayer receives Japanese approval for finerenone to treat patients with chronic heart failure: Berlin Tuesday, December 23, 2025, 14:00 Hrs [IST] Bayer announced that Japan’s Min ...